SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

McInaw Michael

(Last)

(First)

(Middle)

C/O AEVI GENOMIC MEDICINE, INC.

435 DEVON PARK DRIVE, SUITE 715

(Street)

WAYNE

19087

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/01/2019

3. Issuer Name and Ticker or Trading Symbol
Aevi Genomic Medicine, Inc. [ GNMX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Interim CFO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	16,107	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	07/29/2026	Common Stock	6,500	$5.77	D
Stock Option (right to buy)	⁽²⁾	02/17/2027	Common Stock	1,500	$4.91	D
Stock Option (right to buy)	⁽³⁾	06/02/2027	Common Stock	5,000	$1.24	D
Stock Option (right to buy)	⁽⁴⁾	08/11/2027	Common Stock	5,000	$1.32	D
Stock Option (right to buy)	⁽⁵⁾	04/17/2028	Common Stock	26,250	$1.55	D
Stock Option (right to buy)	⁽⁶⁾	01/22/2028	Common Stock	6,500	$1.52	D

Explanation of Responses:

1. One-Third of the option grant vested and became exercisable on each of July 29, 2017 and July 29, 2018 (2,166 options and 2,167 options, respectively), and the rest will vest and become exercisable on July 29, 2019, subject to the reporting person's continued service with the issuer.

2. One-third of the option grant vested and became exercisable on each of February 17, 2018 and February 17, 2019, and the rest will vest and become exercisable on February 17, 2020, subject to the reporting person's continued service with the issuer.

3. One-third of the option grant vested and became exercisable on each of June 2, 2018 and June 2, 2019 (rounded up to the nearest whole share of common stock), and the rest will vest and become exercisable on June 2, 2020, subject to the reporting person's continued service with the issuer.

4. One-third of the option grant vested and became exercisable on August 11, 2018 (rounded up to the nearest whole share of common stock), and the remaining will vest and become exercisable in one-third increments annually on the anniversary of the grant date, subject to the reporting person's continued service with the issuer.

5. One-third of the option grant vested and became exercisable on April 17, 2019, and the remaining will vest and become exercisable in one-third increments annually on the anniversary of the grant date, subject to the reporting person's continued service with the issuer.

6. The options vested and became exercisable on March 30, 2018.

Remarks:

	/s/ Michael McInaw	06/11/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.